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amounted to 75.8%. 56.5% of pts had hypertension and 29.7%
were diabetic. Thirty-four percent of pts were diagnosed as obese
with additional 44.2% of the pts’ population being overweight.
The prevalence of current smokers was 17.5% in total study pop-
ulation and 15.8% in post myocardial infraction pts. Except ACEI
(70.6% vs. 69.5%) drugs such as ASA, LBA, statins were more
frequently applied in secondary prevention group when compared
with primary prevention pts (respectively 54.9% vs. 85.8%, 41.9
vs. 77.0%, 53.8 vs. 79.4%). Underweight pts received fewer rec-
ommendations concerning regular physical activity, dietary coun-
seling and weight loss when compared with obese pts (respectively
80.6% vs. 90.8%; 79.3% vs. 95.3%; 68.8% vs. 97.3%). CON-
CLUSIONS: The POLKARD-SPOK survey conﬁrmed a high
prevalence of modiﬁable risk factors and their inappropriate 
management, in patients with CVD or at high risk of fatal
atherothrombotic events, treated in primary care settings.
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OBJECTIVES: To summarize the diagnostic accuracy of coro-
nary pressure-based fractional ﬂow reserve (FFR) in patients
with suspected coronary artery disease. METHODS: A system-
atic search in literature databases (MEDLINE, EMBASE,
Cochrane and HTA-databases) up to 2005 was performed to
identify published studies comparing FFR with a functional ref-
erence standard and reporting test characteristics. As reference
standard SPECT, scintigraphy or combinations of several tests
(e.g. stress electrocardiography, stress echocardiography, angiog-
raphy) were accepted. We constructed diagnostic 2 × 2-tables
from diagnostic test characteristics (e.g., sensitivity, speciﬁcity)
and performed a diagnostic meta-analysis using the inverse 
variance approach. RESULTS: Thirteen articles were identiﬁed
matching the inclusion criteria. Four articles were excluded
because of multiple reporting of data. From the 9 studies
included, data for 717 observational units (i.e., patient or coro-
nary lesion) were extracted. Pooled sensitivity of FFR was 82%
(95%-CI: 77–86%), and speciﬁcity was 79% (74–83%). Diag-
nostic odds ratio was 16.5 (11.4–63.7). Excluding single studies
did not affect these results. Subgroup analyses showed severity
of disease reﬂected by the number of affected coronary vessels
as an inﬂuential factor on test sensitivity (single-vessel-disease:
95% [87–99%] vs. 78% [73–83%] in multi-vessel-disease).
Choice of reference standard also inﬂuenced pooled sensitivity.
Studies using SPECT as reference standard showed a lower 
sensitivity than studies using other reference standards (78%
[73–83%] vs. 95% [87–99%]). Subgroups of studies with multi-
vessel-disease patients and studies using SPECT as reference stan-
dard tended to be of newer publication date. CONCLUSIONS:
FFR is a functional test with sufﬁciently high sensitivity and
speciﬁcity for the detection of hemodynamic relevant coronary
stenoses. Time trends in the data affecting the overall estimate
of pooled sensitivity can not be excluded, but are unlikely to rel-
evantly inﬂuence the result.
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OBJECTIVE: Drug-eluting stents (DES) have become the prin-
cipal coronary artery revascularization modality in the US; yet
little is known about their long-term clinical outcomes versus
bare-metal stents (BMS). We examined 2-year clinical event rates
for BMS vs. DES in a practice-based population and compared
results for patients with single- as well as multi-vessel coronary
artery disease (CAD). METHODS: The study population
includes Duke University Medical Center patients undergoing
revascularization with BMS or DES between January 1, 2000
and May 31, 2005, with follow-up through August 17, 2006.
Study outcomes examined are death, non-fatal myocardial
infarction (MI), and target vessel revascularization (TVR), and
their composites. RESULTS: We examined the data of 3678 BMS
and 1689 DES patients. DES vs. BMS patients had more multi-
vessel CAD (42.6% vs. 36.6%). At two years follow-up, DES vs.
BMS patients had lower rates of mortality (7.8% vs. 8.6%), non-
fatal MI (3.3% vs. 5.0%), and TVR (6.0% vs. 14.2%). This dif-
ference in DES vs. BMS TVR rate was observed in patients with
1- (5.5% vs. 13.0%), 2- (6.7% vs. 15.7%), and 3-vessel CAD
(7.0% vs. 18.8%). After adjustment for differences in baseline
characteristics using Cox proportional hazards modeling, DES
vs. BMS use was associated with no difference in mortality; but
with signiﬁcant reductions in the composites of death or MI (HR
= 0.81, 95% CI = 0.67, 0.98) and death, MI, or TVR (HR =
0.55, 95% CI = 0.47, 0.64). Event reduction in the adjusted
models was not limited to 1-, 2-, or 3-vessel CAD patients. CON-
CLUSIONS: The use of drug-eluting vs. bare-metal stents is 
associated with signiﬁcant improvements in long-term clinical
outcomes for patients with single- and multi-vessel coronary
artery disease.
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OBJECTIVES: Scottish Intercollegiate Guidelines Network
(SIGN) guidelines advise that at risk patients should be treated
to a total cholesterol (TC) target of <5 mmol/L. Recent Joint
British Societies Guidelines (JBS2, 2005) recommend patients be
treated to a lower TC target of <4 mmol/L. An audit was con-
ducted to determine the effect of the new guidelines on the 
proportion of patients achieving target cholesterol levels with
rosuvastatin. METHODS: General Practice records were
searched to identify patients who had been prescribed rosuvas-
tatin 10 mg and the following data recorded: previous statin
therapy, last cholesterol result on that statin and ﬁrst cholesterol
test on rosuvastatin 10 mg. RESULTS: A total of 508 patients
who had previously been prescribed rosuvastatin 10 mg were
identiﬁed. Of these 376 had both a pre- and post-rosuvastatin
treatment total cholesterol test. The majority of patients were
statin-naive (n = 253), the others had previously been prescribed
atorvastatin, mean dose 14 mg (n = 102), simvastatin mean dose
19 mg (n = 22) or pravastatin mean dose 15 mg (n = 2). Prior to
treatment with rosuvastatin 13% (49/376) had a TC <5 mmol/L,
increasing to 81% (303/376) after treatment with rosuvastatin
10 mg. In previously statin naïve patients 82% (208/253)
achieved TC <5 mmol/L on rosuvastatin compared to 77%
(95/123) in patients who had previously been treated with
another statin. On average patients experienced a 1.6 mmol/L
(27%) reduction in TC (32% in statin naïve, 16% where statin
changed). Improvements were also seen against JBS2 targets;
patients with TC <4 mmol/L improved from 3% (11/376) prior
to rosuvastatin to 35% (131/376) on rosuvastatin 10 mg (37%
in statin naïve, 30% where statin changed). CONCLUSIONS:
